ELEDON PHARMACEUTICALS INC (ELDN) Stock Price, Forecast & Analysis
USA - NASDAQ:ELDN - US28617K1016 - Common Stock
ELDN Key Statistics, Chart & Performance
The current stock price of ELDN is 2.13 USD. In the past month the price decreased by -21.4%. In the past year, price decreased by -46.75%.
ELDN Latest News, Press Relases and Analysis
ELDN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.78B | ||
| AMGN | AMGEN INC | 15.48 | 182.21B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.99 | 71.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 886.18 | 59.24B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.53 | 23.39B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.4 | 20.77B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.24 | 14.61B |
Related stock screener links
About ELDN
Company Profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Company Info
ELEDON PHARMACEUTICALS INC
19800 Macarthur Blvd., Suite 250
Irvine CALIFORNIA 92612 US
CEO: David-Alexandre C. Gros
Employees: 31
Phone: 19492388090
ELEDON PHARMACEUTICALS INC / ELDN FAQ
What does ELDN do?
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
What is the stock price of ELEDON PHARMACEUTICALS INC today?
The current stock price of ELDN is 2.13 USD. The price decreased by -5.33% in the last trading session.
Does ELEDON PHARMACEUTICALS INC pay dividends?
ELDN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ELDN stock?
ELDN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for ELDN stock?
13 analysts have analysed ELDN and the average price target is 9.79 USD. This implies a price increase of 359.72% is expected in the next year compared to the current price of 2.13.
Would investing in ELEDON PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ELDN.
Who owns ELEDON PHARMACEUTICALS INC?
You can find the ownership structure of ELEDON PHARMACEUTICALS INC (ELDN) on the Ownership tab.
ELDN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ELDN. When comparing the yearly performance of all stocks, ELDN is a bad performer in the overall market: 92.08% of all stocks are doing better.
ELDN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELDN. While ELDN has a great health rating, there are worries on its profitability.
ELDN Financial Highlights
Over the last trailing twelve months ELDN reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS increased by 106.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.12% | ||
| ROE | -9.73% | ||
| Debt/Equity | 0 |
ELDN Forecast & Estimates
13 analysts have analysed ELDN and the average price target is 9.79 USD. This implies a price increase of 359.72% is expected in the next year compared to the current price of 2.13.